Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Enhanced tumor immunogenicity through coupling cytokine expression with antigen presentation

Abstract

The density of tumor antigen in conjunction with major histocompatibility complex (MHC) class I molecules on the cell surface affects cytotoxic T cell (CTL) function in an active antitumor immune response. Thus, methods to enhance antigen expression/presentation could augment the effect of cancer immune therapy. In the present study, we investigated the feasibility of modifying a cytokine signal peptide with a tumor antigenic epitope. We inserted the genes encoding the MHC class I-restricted antigenic epitope of chicken ovalbumin and tyrosinase-related protein 2 into the signal sequence of the interleukin-2 gene, replacing part of the signal sequence at different positions. Our results showed that these modified signal peptides still functioned, as indicated by cytokine secretion. The antigenic epitope within the modified signal peptide could be processed properly and presented on tumor cell surface. Tumor cells demonstrated enhanced immunogenicity as indicated by increased susceptibility to CTL lysis in vitro and decreased tumor grow in vivo after gene modification. These data provide potential perspectives in designing therapeutic or vaccine strategies in immuno-gene therapy of cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Lefebvre S, Moreau P, Dausset J, Carosella ED, Paul P . Downregulation of HLA class I gene transcription in choriocarcinoma cells is controlled by the proximal promoter element and can be reversed by CIITA. Placenta. 1999;20:293–301.

    Article  CAS  Google Scholar 

  2. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C . Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 2001;61:1095–1099.

    CAS  Google Scholar 

  3. McAdam AJ, Felcher A, Woods ML, et al. Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes. J Immunother Emphasis Tumor Immunol. 1994;15:155–164.

    Article  CAS  Google Scholar 

  4. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328–332.

    Article  CAS  Google Scholar 

  5. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A . Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer. 1996;66:470–476.

    Article  CAS  Google Scholar 

  6. Lehmann F, Marchand M, Hainaut P, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol. 1995;25:340–347.

    Article  CAS  Google Scholar 

  7. Gilmore R, Blobel G, Walter P . Protein translocation across the endoplasmic reticulum. I. Detection in the microsomal membrane of a receptor for the signal recognition particle. J Cell Biol. 1982;95:463–469.

    Article  CAS  Google Scholar 

  8. Walter P, Johnson AE . Signal sequence recognition and protein targeting to the endoplasmic reticulum membrane. Annu Rev Cell Biol. 1994;10:87–119.

    Article  CAS  Google Scholar 

  9. Henderson RA, Michel H, Sakaguchi K, et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science. 1992;255:1264–1266.

    Article  CAS  Google Scholar 

  10. Uger RA, Barber BH . Presentation of an influenza nucleoprotein epitope incorporated into the H-2Db signal sequence requires the transporter-associated with antigen presentation. J Immunol. 1997;158:685–692.

    CAS  PubMed  Google Scholar 

  11. Khanna R, Burrows SR, Argaet V, Moss DJ . Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int Immunol. 1994;6:639–645.

    Article  CAS  Google Scholar 

  12. Sherritt M, Cooper L, Moss DJ, Kienzle N, Altman J, Khanna R . Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters. Int Immunol. 2001;13:265–271.

    Article  CAS  Google Scholar 

  13. von Heijne G . The signal peptide. J Membr Biol. 1990;115:195–201.

    Article  CAS  Google Scholar 

  14. Rotzschke O, Falk K, Stevanovic S, Jung G, Walden P, Rammensee HG . Exact prediction of a natural T cell epitope. Eur J Immunol. 1991;21:2891–2894.

    Article  CAS  Google Scholar 

  15. Harada M, Tamada K, Abe K, et al. Characterization of B16 melanoma-specific cytotoxic T lymphocytes. Cancer Immunol Immunother. 1998;47:198–204.

    Article  CAS  Google Scholar 

  16. Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y . Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 1998;58:4895–4901.

    CAS  PubMed  Google Scholar 

  17. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR . T cell receptor antagonist peptides induce positive selection. Cell. 1994;76:17–27.

    Article  CAS  Google Scholar 

  18. Moore MW, Carbone FR, Bevan MJ . Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 1988;54:777–785.

    Article  CAS  Google Scholar 

  19. Geiser M, Cebe R, Drewello D, Schmitz R . Integration of PCR fragments at any specific site within cloning vectors without the use of restriction enzymes and DNA ligase. Biotechniques. 2001;31:88–90, 92.

    Article  CAS  Google Scholar 

  20. Gillis S, Smith KA . Long term culture of tumour-specific cytotoxic T cells. Nature. 1977;268:154–156.

    Article  CAS  Google Scholar 

  21. Sladowski D, Steer SJ, Clothier RH, Balls M . An improved MTT assay. J Immunol Methods. 1993;157:203–207.

    Article  CAS  Google Scholar 

  22. Karttunen J, Shastri N . Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene. Proc Natl Acad Sci USA. 1991;88:3972–3976.

    Article  CAS  Google Scholar 

  23. Bednarek AK, Keck-Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. 2001;61:8068–8073.

    CAS  PubMed  Google Scholar 

  24. Barth Jr RJ, Mule JJ, Spiess PJ, Rosenberg SA . Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med. 1991;173:647–658.

    Article  CAS  Google Scholar 

  25. Paillard F . Immuno-gene therapy for myeloma using cytokines. Hum Gene Ther. 1998;9:1–2.

    Article  CAS  Google Scholar 

  26. Heinzerling LM, Feige K, Rieder S, et al. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med. 2001;78:692–702.

    Article  CAS  Google Scholar 

  27. Blobel G, Dobberstein B . Transfer of proteins across membranes. I. Presence of proteolytically processed and unprocessed nascent immunoglobulin light chains on membrane-bound ribosomes of murine myeloma. J Cell Biol. 1975;67:835–851.

    Article  CAS  Google Scholar 

  28. Blobel G, Dobberstein B . Transfer to proteins across membranes. II. Reconstitution of functional rough microsomes from heterologous components. J Cell Biol. 1975;67:852–862.

    Article  CAS  Google Scholar 

  29. Kaiser CA, Preuss D, Grisafi P, Botstein D . Many random sequences functionally replace the secretion signal sequence of yeast invertase. Science. 1987;235:312–317.

    Article  CAS  Google Scholar 

  30. Gallimore A, Schwarz K, van den BM, Hengartner H, Groettrup M . The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope. Mol Immunol. 1998;35:581–591.

    Article  CAS  Google Scholar 

  31. Bai A, Forman J . The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules. J Immunol. 1997;159:2139–2146.

    CAS  PubMed  Google Scholar 

  32. Yewdell JW, Snyder HL, Bacik I, et al. TAP-independent delivery of antigenic peptides to the endoplasmic reticulum: therapeutic potential and insights into TAP-dependent antigen processing. J Immunother. 1998;21:127–131.

    Article  CAS  Google Scholar 

  33. Guilloux Y, Bai XF, Liu X, Zheng P, Liu Y . Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells. Cancer Res. 2001;61:1107–1012.

  34. Qin Z, Harders C, Cao X, Huber C, Blankenstein T, Seliger B . Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. Cancer Res. 2002;62:2856–2860.

    CAS  PubMed  Google Scholar 

  35. Valitutti S, Muller S, Dessing M, Lanzavecchia A . Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med. 1996;183:1917–1921.

    Article  CAS  Google Scholar 

  36. Tso CL, Zisman A, Pantuck A, et al. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res. 2001;61:7925–7933.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Debbie Sakiestewa and Domonic Titone for their excellent technical support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David T Harris.

Rights and permissions

Reprints and permissions

About this article

Cite this article

He, X., Tsang, T., Luo, P. et al. Enhanced tumor immunogenicity through coupling cytokine expression with antigen presentation. Cancer Gene Ther 10, 669–677 (2003). https://doi.org/10.1038/sj.cgt.7700618

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700618

Keywords

This article is cited by

Search

Quick links